Evidence map›Paper›PMID 36726173›Full record

ArticleCancer cell international2023

Environmental signals perceived by the brain abate pro-metastatic monocytes by dampening glucocorticoids receptor signaling.

María Magdalena Canali, Mélanie Guyot, Thomas Simon, Douglas Daoudlarian, Joelle Chabry, Clara Panzolini, Agnès Petit-Paitel, Nicolas Hypolite, Sarah Nicolas, Pierre Bourdely and 10 more

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 2 countries.

María Magdalena Canali *Molecular and Cellular Pharmacology Institute, Université Côte d'Azur, CNRS, 660 Route des Lucioles, Valbonne, France.
Mélanie Guyot *Molecular and Cellular Pharmacology Institute, Université Côte d'Azur, CNRS, 660 Route des Lucioles, Valbonne, France.
Thomas SimonMolecular and Cellular Pharmacology Institute, Université Côte d'Azur, CNRS, 660 Route des Lucioles, Valbonne, France.
Douglas DaoudlarianMolecular and Cellular Pharmacology Institute, Université Côte d'Azur, CNRS, 660 Route des Lucioles, Valbonne, France.
Joelle ChabryMolecular and Cellular Pharmacology Institute, Université Côte d'Azur, CNRS, 660 Route des Lucioles, Valbonne, France.
Clara PanzoliniMolecular and Cellular Pharmacology Institute, Université Côte d'Azur, CNRS, 660 Route des Lucioles, Valbonne, France.
Agnès Petit-PaitelMolecular and Cellular Pharmacology Institute, Université Côte d'Azur, CNRS, 660 Route des Lucioles, Valbonne, France.
Nicolas HypoliteMolecular and Cellular Pharmacology Institute, Université Côte d'Azur, CNRS, 660 Route des Lucioles, Valbonne, France.
Sarah NicolasMolecular and Cellular Pharmacology Institute, Université Côte d'Azur, CNRS, 660 Route des Lucioles, Valbonne, France.
Pierre BourdelyMolecular and Cellular Pharmacology Institute, Université Côte d'Azur, CNRS, 660 Route des Lucioles, Valbonne, France.
Heidy Schmid-AntomarchiUniversité Côte d'Azur, CNRS, INSERM, Valrose Biology Institute, 28 Avenue de Valombrose, Nice, France.
Annie Schmid-AllianaUniversité Côte d'Azur, CNRS, INSERM, Valrose Biology Institute, 28 Avenue de Valombrose, Nice, France.
Javier SoriaMolecular and Cellular Pharmacology Institute, Université Côte d'Azur, CNRS, 660 Route des Lucioles, Valbonne, France.
Babou Karimdjee SoilihiUniversité Côte d'Azur, CNRS, INSERM, Valrose Biology Institute, 28 Avenue de Valombrose, Nice, France.
Paul HofmanLaboratory of Clinical and Experimental Pathology and Biobank, Nice University Hospital, Nice, France.
Armelle Prevost-BlondelUniversité Paris Descartes, CNRS, INSERM, Institut Cochin, 22 rue Méchain, 75014, Paris, France.
Masashi KatoDepartment of Occupational and Environmental Health, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Evelyne MougneauMolecular and Cellular Pharmacology Institute, Université Côte d'Azur, CNRS, 660 Route des Lucioles, Valbonne, France.
Nicolas Glaichenhaus *Molecular and Cellular Pharmacology Institute, Université Côte d'Azur, CNRS, 660 Route des Lucioles, Valbonne, France.
Philippe Blancou *Molecular and Cellular Pharmacology Institute, Université Côte d'Azur, CNRS, 660 Route des Lucioles, Valbonne, France. blancou@ipmc.cnrs.fr.
Centre National de la Recherche Scientifique · FRInstitut de Pharmacologie Moléculaire et Cellulaire · FRInserm · FRNagoya University · JPUniversité Côte d'Azur · FR

Funding

Agence Nationale de la Recherche AsthmaTreatLABEX SIGNALIFE ANR-11-LABX-0028-01
6 · The paper itself

Abstract

While positive social-behavioral factors predict longer survival in cancer patients, the underlying mechanisms are unknown. Since tumor metastasis are the major cancer mortality factor, we investigated how an enriched environment (EE) conductive to enhanced sensory, cognitive and motor stimulation impact metastatic progression in lungs following intravasation in the circulation. We find that mice housed in EE exhibited reduced number of lung metastatic foci compared to control mice housed in a standard environment (SE). Compared to SE mice, EE mice increased lung inflammation as early as 4 days after circulating tumor cells extravasation. The impact of environmental signals on lung metastasis is independent of adrenergic receptors signaling. By contrast, we find that serum corticosterone levels are lower in EE mice and that glucocorticoid receptor (GR) antagonist reduces the number of lung metastasis in SE mice. In addition, the difference of the number of lung metastasis between SE and EE mice is abolished when inflammatory monocytes are rendered deficient in GR signaling. This decreased GR signaling in inflammatory monocytes of SE mice results in an exacerbated inflammatory profile in the lung. Our study shows that not only EE reduces late stages of metastatic progression in lungs but disclose a novel anti-tumor mechanism whereby GR-dependent reprogramming of inflammatory monocytes can inhibit metastatic progression in lungs. Moreover, while inflammatory monocytes have been shown to promote cancer progression, they also have an anti-tumor effect, suggesting that their role is more complex than currently thought.

Identifiers

PMID36726173
PMCPMC9893572
OpenAlexW4318775136

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.